

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

| | |
|-----|---|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No | |
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| N/A | |
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
| N/A | |
| 4. | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
| N/A | |

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

Approved by Associate Director (name): Ian Watson

Date: 14/08/2024

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

Issue date: August 2024

2 of 2